NovoCure’s wearable device receives FDA approval for metastatic cancer treatment

New Delhi: NovoCure, a US-based company, recently received FDA approval for its wearable device to treat metastatic cancer using Tumor Treating Fields (TTFields) technology. This non-invasive device targets cancer cells with electric fields to slow tumor growth, offering a new option for patients who have exhausted other treatments.

The global metastatic cancer treatment market is expected to grow from $63.03 billion in 2019 to $111.16 billion by 2027, driven by advancements in therapies like targeted treatment and immunotherapy. Increased research, investment, and initiatives in regions like India and Japan also contribute to this growth.

Clinical trials showed the device improved survival rates and had fewer side effects compared to chemotherapy and radiation. NovoCure is making the device available in the US and working with healthcare providers to incorporate it into cancer treatment plans.